Partnering to diversify and strengthen our product pipeline
Partnerships with pharmaceutical companies may allow us to access additional development and commercial resources, expertise and non-dilutive funding to enable the advancement of a broader and more diverse pipeline. We have selectively established partnerships that enable us to access large commercial indications while leveraging the benefits of those collaborations to expand our internal capabilities.
To date, our pharmaceutical collaborations have generated in aggregate over $160.0 million in non-equity funding with the potential to provide us with future milestone payments, as well as royalties on product sales. Our current pharmaceutical partners include Genentech, a member of the Roche Group, and Merck & Co., Inc. (through its affiliate, Essex Chemie AG).
For more information about partnering with Xenon, please contact:
Robin Sherrington, PhD
Executive Vice President, Business & Corporate Development